KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Return on Equity (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Return on Equity for 14 consecutive years, with 0.06% as the latest value for Q2 2025.

  • On a quarterly basis, Return on Equity rose 6.0% to 0.06% in Q2 2025 year-over-year; TTM through Jun 2025 was 0.06%, a 6.0% increase, with the full-year FY2024 number at 0.08%, up 7.0% from a year prior.
  • Return on Equity was 0.06% for Q2 2025 at Supernus Pharmaceuticals, up from 0.06% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.15% in Q1 2021 to a low of 0.02% in Q1 2024.
  • A 5-year average of 0.06% and a median of 0.06% in 2025 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: decreased -11bps in 2021, then grew 8bps in 2025.
  • Supernus Pharmaceuticals' Return on Equity stood at 0.07% in 2021, then increased by 6bps to 0.07% in 2022, then crashed by -98bps to 0.0% in 2023, then soared by 296bps to 0.01% in 2024, then surged by 1015bps to 0.06% in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Return on Equity are 0.06% (Q2 2025), 0.06% (Q1 2025), and 0.01% (Q2 2024).